/ACXP
ACXP Stock - Acurx Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$3.33-3.48%
$0.12 (-3.48%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACXP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.30 – $3.36
TARGET (TP)$3.83
STOP LOSS$3.06
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.25
52W High$25.00
52W Low$3.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-14,103,103 | $-14,577,768 | $-12,092,776 | $-12,814,200 | $-4,600,038 |
| Net Income | $-14,103,103 | $-14,577,768 | $-12,092,776 | $-12,747,697 | $-4,600,038 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-17.59 | $-23.01 | $-22.36 | $-24.96 | $-9.28 |
Company Overview
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ACXPBeat Rate
69%
Last 16 quarters
Avg Surprise
-78.0%
EPS vs Estimate
Beats / Misses
11/5
Last 12 quarters
Latest EPS
$-1.23
Q4 2025
EPS Surprise History
Q1 24
-46.2%
$-0.38vs$-0.26
Q2 24
-16.7%
$-0.28vs$-0.24
Q3 24
+7.1%
$-0.26vs$-0.28
Q4 24
+26.1%
$-0.17vs$-0.23
Q1 25
+11.1%
$-0.16vs$-0.18
Q2 25
-1366.7%
$-2.20vs$-0.15
Q3 25
+5.5%
$-1.89vs$-2.00
Q4 25
+23.6%
$-1.23vs$-1.61
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $-1.01 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.61 | $-1.23 | +23.6% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-2.00 | $-1.89 | +5.5% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.15 | $-2.20 | -1366.7% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q1 2024 | Mar 15, 2024 | $-0.26 | $-0.38 | -46.2% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.25 | $-0.28 | -12.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.35 | $-0.26 | +25.7% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.33 | $-0.26 | +21.2% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.40 | $-0.23 | +42.5% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | — | $-0.46 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.57 | — | — |
Q2 2021 | Jun 28, 2021 | — | $-0.11 | — | — |
Latest News
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:02 PM
Acurx Pharmaceuticals Unveils Study Showing First Structural Evidence Of Novel DNA pol IIIC Antibiotic Target; Lead Drug Ibezapolstat Advances Toward Phase 3 To Combat C. difficile and Other Resistant Infections
📈 PositiveBenzinga•Nov 10, 2025, 01:08 PM
Acurx Pharmaceuticals Presents Data On Ibezapolstat Clinical Study Program At Diseases Society of America In Atlanta
➖ NeutralBenzinga•Oct 28, 2025, 12:19 PM
Acurx Pharma Secures Australian Patent For DNA Polymerase IIIC Inhibitors, Expanding ACX-375C Coverage Across Five Countries
📈 PositiveBenzinga•Oct 9, 2025, 11:35 AM
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 03:09 PM
Acurx Pharma Receives Favorable Opinion From PDCO Of EMA On Acurx's Pediatric Investigation Plan For Ibezapolstat Use In Children With C. Difficile Infection
📈 PositiveBenzinga•Sep 30, 2025, 11:34 AM
Acurx Pharmaceuticals Regains Compliance With Nasdaq Minimum Closing Bid Price And Stockholder Equity Requirements
📈 PositiveBenzinga•Sep 3, 2025, 01:14 PM
Frequently Asked Questions about ACXP
What is ACXP's current stock price?
Acurx Pharmaceuticals, Inc. (ACXP) is currently trading at $3.33 per share. The stock has moved -3.48% today.
What is the analyst price target for ACXP?
No analyst price targets are currently available for this stock.
What sector is Acurx Pharmaceuticals, Inc. in?
Acurx Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACXP's market cap?
Acurx Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ACXP pay dividends?
No, Acurx Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
BCLI
Brainstorm Cell Therapeutics Inc.
$0.56
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
Explore stocks similar to ACXP for comparison